Table 3. Proportion of COVID-19 patients with venous thromboembolism: sensitivity analysis of all hospitalized patients.
| Subcategories in all hospitalized patients | No. of total Patients | Percentage of patients with VTE | 95% CI |
|---|---|---|---|
| Study type | |||
| • Prospective | 4,661 | 11.888 | 7.444–17.203 |
| • Retrospective | 28,006 | 11.470 | 9.737–13.325 |
| • Cross sectional | 838 | 13.597 | 5.419–24.721 |
| • Case series | 1,420 | 34.015 | 7.494–67.865 |
| • Other design | 92 | 29.870 | 21.133–39.417 |
| Screening mode | |||
| • Mandatory | 6,141 | 18.587 | 14.018–23.638 |
| • Symptom triggered | 18,623 | 11.522 | 9.224–14.039 |
| Thromboprophylaxis | |||
| • No prophylaxis | 1,289 | 13.449 | 5.209–24.750 |
| • Prophylactic dose | 15,220 | 12.899 | 10.344–15.691 |
| • Intermediate dosing | 186 | 10.450 | 0.545–30.445 |
| • Multiple dosing | 14,550 | 12.705 | 10.003–15.678 |
| • Prophylaxis not reported | 3,762 | 12.838 | 7.578–19.234 |
| Sample size | |||
| • 5th quintile | 27,569 | 5.495 | 4.281–6.850 |
Abbreviations: CI, confidence interval; COVID-19, novel coronavirus disease 2019; VTE, venous thromboembolism.